Human Metabolome Technologies, Inc. (HMT), the leading developer of capillary electrophoresis mass spectrometry (CE-MS) based metabolomics, released an analysis service offering cancer metabolism profiling, CARCINOSCOPE.
A Brief Introduction to HMT
Human Metabolome Technologies (HMT) is a Japan-based biotechnology company developing capillary electrophoresis mass spectrometry (CE-MS) based metabolomics technologies and solution to drive drug discovery, diagnosis, and food production. Our research and development methodology are at the heart of an emerging field of metabolomics and systems biology.
F-SCOPE, a quantitative 13C/15N labeling analysis, provides a unique snapshot of metabolic changes in your research setting.
Learn more about HMT and our Technology
HMT America Members discuss what makes HMT so unique
HMT Webinar Series: Isotope Analyses
Isotope Analyses – Modeling the Ever-Changing Metabolomic Landscape
HMT And Pharmalegacy Laboratories (Shanghai) Announced A Strategic Partnership
The scope of partnership includes information sharing and co-operation in sales and marketing activities in order to help each other’s growth in the overseas market.
Published in Psychiatry and Clinical Neurosciences
The First diagnostic plasma metabolite biomarker for Major Depression Disorder (MDD) has been published in Psychiatry and Clinical Neurosciences.
HMT and Toyobo and MDD
HMT and Toyobo have established production of Ethanolaminephosphate phospho-lyase for clinical assay relating Major Depression Disorder (MDD).